These data, when combined with the characterization of immunosuppressive markers PD-L1 and PD-L2 on CD33+ monocytes and CD66b+ granulocytes (Fig. 4) generates information as to the degree of immunosuppression present in the tumor and, hence, may predict potential response to immunomodulatory drugs. Here, PDCD1LG2 is linked to neoplasm.